PRESS RELEASE : CureVac Broadcasts Appointment of Dr. Malte Greune as Chief Working Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Improvement of The RNA Printer(R)

DGAP-News: CureVac / Key word (s): Personal CureVac announces the appointment of Dr. Malte Greune as Chief Operating Officer and change from Dr. Florian von der Mülbe announced as head of the accelerated development of the RNA Printer (R) 06/30/2021 / 13:00 The issuer is solely responsible for the content of this announcement. = ————————————————- ————————————————– ——————- CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and transition from Dr. Florian von der Mülbe as Head of Accelerated Development of the RNA Printer (R) TÜBINGEN, Germany / BOSTON, USA – June 30, 2021 – CureVac NV (Nasdaq: CVAC), a global biopharmaceutical company in clinical phase, introducing a new class transformative drugs developed on the basis of messenger ribonucleic acid (“mRNA”), announced today the appointment of Dr. Malte Greune as Chief Operating Officer (COO) with effect from July 1, 2021. In this position, he will strengthen the company’s Executive Board and, among other things, lead the clinical and commercial manufacturing activities of CureVac. Dr. Greune comes to CureVac with extensive experience in the global pharmaceutical industry, including manufacturing vaccines and filling and refining biologicals. CureVac also announced that Dr. Florian von der Mülbe, Co-Founder and Chief Production Officer, will now focus his extensive production expertise exclusively on the expansion and accelerated development of The RNA Printer (R), CureVac’s solution for mobile, autonomous and fully automated manufacturing of RNA vaccines and therapeutics in GMP quality. In order to advance this key strategic project, which requires the development of its own operational infrastructure, Dr. von der Mülbe resign from the board of CureVac NV. Dr. Greune takes over the board position from Dr. from the trash. “On behalf of the Supervisory Board, my name is Dr. Greune welcome to the board. Dr. Greune is a recognized expert in the global pharmaceutical industry with many years of experience in various management positions. His appointment is a great addition to CureVac as the company continues to grow and expand its one-stop-shop strategy for RNA-based vaccines and therapeutics with strong manufacturing capabilities, “said Jean Stéphenne, Chairman of the Board of Directors of CureVac . von der Mülbe for his work on the CureVac board of directors. As a co-founder of CureVac, he has been instrumental in building the company and building its strong manufacturing expertise, to which he will now move to ensure that The RNA Printer (R) is another important one Will be a growth driver for the company. ” Dr. Greune comes to CureVac from Sanofi-Aventis Deutschland GmbH, where he held various management positions for almost ten years. As General Manager and Vice President Cartridges, Devices & Insulin Technology Group, he was responsible for several production sites in Frankfurt. Under his leadership, six isolator filling lines for insulins, oncology drugs and biologics were set up, including one for a COVID-19 vaccine. Prior to his position as Head of Diabetes, Oncology and Devices at Sanofi, he worked as Senior Vice President of Animal Health Manufacturing for the Merck Manufacturing Division, USA, where he managed an international network of 28 locations – including 18 integrated vaccine sites. He also held various management positions at the pharmaceutical companies Schering-Plow and Intervet International BV. Dr. Greune began his career at Hoechst AG in corporate planning. Dr. Greune received his Ph.D. in Economics from the University of Cologne, Germany, graduated from the University of Trier, Germany, and completed a Master of Business Administration from Clark University in Worcester, USA. “Dr. Greune has extensive expertise in the international pharmaceutical sector that will further benefit the growth of CureVac,” said Dr. Greune. Franz-Werner Haas, CEO of CureVac. “We are confident that his outstanding experience will help us accelerate our development from a science-driven to a commercial pharmaceutical company. I want to Dr. We would like to thank Florian von der Mülbe for combining the founder’s mindset with a growing commercialized company that he will continue to provide. ”“ Strong manufacturing capabilities are an important part of our corporate strategy and I am proud of what we have built together in this area over the past 21 years, “said Dr. Florian von der Mülbe.” I am delighted that Dr. Greune is taking over to further develop our manufacturing capabilities and I look forward to using all of my strength and expertise to speed up The RNA Printer (R) as an accelerator in the RNA field. ”“ It’s a great pleasure to have CureVac in such a way This is an exciting phase in the company’s transformation that focuses on a diversified RNA-based product pipeline for various indications, “added Dr. Malte Greune.” This technology is just beginning to transform today’s medicine. I look forward to taking on this important role in bringing multiple mRNA drugs to market that can improve human health around the world. “About CureVac CureVac is a global messenger RNA (mRNA) biopharmaceutical company -Technology with more than 20 years of experience in developing and optimizing the versatile biological molecule for medical use.The principle behind CureVac’s proprietary technology is to use non-chemically modified mRNA as a data carrier to instruct the human body to make its own proteins That can fight a wide variety of diseases. Based on its proprietary technology, the company has built an extensive clinical pipeline in prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac went public on the New York City Nasdaq on August 20 20. It is headquartered in Tübingen, Germany, and employs more than 700 people in locations in Tübingen, Frankfurt, and Boston, USA. More information is available at www.curevac.com. CureVac Investor Relations Contact Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations CureVac, Tübingen, Germany T: +49 7071 9883-1298 M: +49 160 90 496949 sarah.fakih@curevac.com CureVac Media Contact Anna Kamilli, Manager Communication CureVac, Tübingen, Germany T : +49 7071 9883-1684 anna.kamilli@curevac.com Bettina Jödicke-Braas, Head of Communication CureVac, Tübingen, Germany T: 49 7071 9883-1087 bettina.joedicke-braas@curevac.com -Forward-looking statements This press release contains statements which constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995, including statements expressing opinions, expectations, beliefs, plans, goals, beliefs or projections by CureVac NV and / or its wholly-owned subsidiaries, CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the “Company”) with regard to future events or he future results, as opposed to statements that reflect historical facts. Examples include discussions about the potential effectiveness of the company’s vaccine and treatment candidates, as well as the company’s strategies, funding plans, growth opportunities, and market growth. In some instances, such forward-looking statements can be identified by terms such as “anticipate”, “intend”, “believe”, “estimate”, “plan”, “aim”, “project” or “expect”. may, “will”, “would”, “could”, “potentially”, “intend” or “should”, the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and information currently available to the company. However, these forward-looking statements are not and you should not place any reliance on them. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative global economic conditions and continued instability and volatility in the global financial markets, the ability to raise funds, the ability to conduct current and future preclinical and clinical studies, the timing, costs and uncertainty of regulatory approval, dependence on third parties and cooperation partners, ability to market ng of products, ability to manufacture any product, possible changes in applicable and proposed laws, regulations and government policies, pressures from increased competition and consolidation in the business industry, the impact of the COVID-19 pandemic on the business and results of the company, the Ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to maintain patient safety, and the variability in operating results due to the effects of exchange rates or factors. Such risks and uncertainties could cause statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are beyond the control of the company and could cause actual results to differ materially from those expected. The forward-looking statements contained in this press release speak only as of the date of this press release. The company assumes no obligation, and in particular does not disclaim any obligation, to update such statements or to publicly announce the results of any revision of such statements to reflect future events or developments, unless this is required by law. For more information, see the company’s reports and documents filed with the SEC. You can obtain these documents by visiting EDGAR on the SEC website at www.sec.gov. = ————————————————- ————————————————– ——————-

(FOLLOW MORE) Dow Jones Newswires

June 30, 2021 7:02 AM ET (11:02 AM GMT)